Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Essai prospectif de gastroplastie par manchon endoscopique (ESG) pour l'obésité (EGO-Trial)

3 novembre 2026 mis à jour par: IHU Strasbourg

Essai prospectif de gastroplastie endoscopique manchonnée (ESG) pour l'obésité

EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions

The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

Obesity, particularly morbid obesity, is a major public health issue in France. According to the latest data from the ObÉpi-Roche 2020 survey, more than 17% of French adults are obese. Obesity is a well-established risk factor for many chronic diseases such as type 2 diabetes, cardiovascular disease, high blood pressure (HBP), musculoskeletal disorders, certain cancers, and non-alcoholic steatohepatitis (NASH). It is associated with a significant reduction in life expectancy and represents a direct cost estimated at more than €5 billion per year for the French healthcare system.

While bariatric surgery (particularly sleeve gastrectomy and gastric bypass) remains the gold standard treatment for severe obesity, it is invasive, costly, and only offered to a minority of patients (less than 10% of eligible patients). In addition, certain medical contraindications, refusal of surgery, and waiting times limit access to this treatment.

Endoscopic sleeve gastroplasty ("Endosleeve"). Endoscopic sleeve gastroplasty (ESG) is an innovative, non-surgical, natural procedure that reduces stomach volume without resection or anastomosis. It has shown promising results in terms of weight loss, metabolic improvement, and safety, while being reversible and reproducible. The MERIT randomized controlled trial in USA (JAMA, 2022) demonstrated an average weight loss of 13.6% of total body weight at 12 months (vs. 0.8% in the control group), as well as a significant improvement in comorbidities such as type 2 diabetes and hypertension.

Hypothesis and objective of the study The hypothesis of this study is that ESG, when performed under routine care conditions in the United States, leads to significant and sustainable weight loss, associated with an improvement in comorbidities, with a favorable safety profile. The main objective of this project is therefore to evaluate, on a national scale, the clinical efficacy, safety, and procedural variability of ESG through a multicenter real-world cohort.

To date, no large-scale French study has analyzed the results of ESG in real-world settings. This hinders its integration into national healthcare pathways, its reimbursement by the French national health insurance system, and its wider adoption by the medical community. The question raised-the rigorous evaluation of ESG in the French context-therefore remains unanswered.

This project aims to generate robust data representative of the national clinical reality in order to support the supervised development of ESG. Expected outcomes include the publication of scientific articles in peer-reviewed journals, the presentation of results at international conferences, contributions to health technology assessment work, and the establishment of a national registry of endoscopic gastroplasty. This work could represent a major advance in the therapeutic arsenal for obesity, supporting the integration of ESG as a recognized, validated, and reimbursed option in French healthcare pathways.

Type d'étude

Observationnel

Inscription (Estimé)

300

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Aix-en-Provence, France
        • Recrutement
        • Hôpital Privé de Provence
        • Contact:
      • Besançon, France
        • Pas encore de recrutement
        • Polyclinique de Franche-Comté
        • Contact:
      • Lille, France
        • Pas encore de recrutement
        • Hôpital HURIEZ
        • Contact:
      • Lyon, France
      • Lyon, France
        • Recrutement
        • Hospices Civils de Lyon - Hôpital Edourard HERRIOT
        • Contact:
      • Montpellier, France
        • Pas encore de recrutement
        • Clinique Clémentville
        • Contact:
      • Saint-Etienne, France
        • Pas encore de recrutement
        • Centre Mutualiste de l'Obésité
        • Contact:
      • Saint-Grégoire, France
        • Pas encore de recrutement
        • CHP Saint-Grégoire
        • Contact:
      • Strasbourg, France
        • Recrutement
        • Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil
        • Contact:
      • Sète, France
        • Recrutement
        • Polyclinique Sainte Thérèse
        • Contact:
      • Échirolles, France
      • Baie-Mahault, Guadeloupe
        • Pas encore de recrutement
        • Clinique les Eaux Claires
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Adult patients with obesity scheduled for endoscopic gastroplasty

La description

Inclusion Criteria:

  • Patients aged 18 to 75 years.
  • Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
  • Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
  • Patients not eligible for bariatric surgery or does not wish to undergo it.
  • Patients who can undergo general anesthesia.
  • Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
  • Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
  • Patients affiliated with the French social security system.

Exclusion Criteria:

  • Patients with contraindications to endoscopic gastroplasty
  • Patients with active peptic ulcer disease or significant gastroparesis
  • Patients with a history of bariatric, gastric, or esophageal surgery.
  • Patients who have started medication in the last 3 months that is known to cause weight gain.
  • Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
  • Patients with unstable and precarious health, as determined and assessed by the investigator.
  • Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
  • Patients who are currently excluded (as determined by a previous or ongoing study).
  • Patients under judicial protection.
  • Patients under guardianship, conservatorship or subject to any form of protective supervision

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: CASE_ONLY
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Tous les patients adultes obèses programmés pour une gastroplastie endoscopique (ESG)

Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Total Body Weight Loss
Délai: At the inclusion and 24 months after procedure

Assessment of weight loss in terms of total body weight loss (TBWL, %) 24 months after surgery

At the inclusion and 24 months after procedure

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Excess weight loss
Délai: At the inclusion and 24 months after procedure

Assessment of weight loss in terms of excess weight loss (EWL, %) at 24 months post-procedure

At the inclusion and 24 months after procedure
Body Mass Index (BMI)
Délai: From ESG procedure to the end of participation at 24 months post-procedure

Assessment of weight loss in terms of change in Body Mass Index (BMI) at 24 months post-procedure

From ESG procedure to the end of participation at 24 months post-procedure
Adverse events
Délai: From ESG procedure to the end of participation at 24 months post-procedure

Rate of minor and major adverse events (e.g., perforation, delayed gastric emptying, reflux symptoms) throughout follow-up for up to 24 months post-procedure

From ESG procedure to the end of participation at 24 months post-procedure
Comorbidities improvement
Délai: From ESG procedure to the end of participation at 24 months post-procedure

Assessment of improvement in comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea) and obesity-related complications over 24 months using the SF-BARI (Swiss-Finnish BARIatric metabolic outcome score) questionnaire: a score developed to evaluate treatment outcomes in obesity management

From ESG procedure to the end of participation at 24 months post-procedure
Quality of life improvement
Délai: From ESG procedure to the end of participation at 24 months post-procedure

Assessment of quality of life over 24 months using the GIQLI (Gastrointestinal Quality of Life Index) questionnaire: digestive quality of life score comprising 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments

From ESG procedure to the end of participation at 24 months post-procedure
Additional treatments
Délai: From ESG procedure to the end of participation at 24 months post-procedure

Compilation of additional treatments or revisions required after the procedure

From ESG procedure to the end of participation at 24 months post-procedure

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Silvana PERRETTA, MD-PhD, Hôpitaux Universitaires de Strasbourg

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

17 mars 2026

Achèvement primaire (Estimé)

1 mars 2030

Achèvement de l'étude (Estimé)

1 mars 2030

Dates d'inscription aux études

Première soumission

27 février 2026

Première soumission répondant aux critères de contrôle qualité

27 février 2026

Première publication (Réel)

4 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner